CSS
IMNM icon

Cubist Systematic Strategies’s Immunome IMNM Stock Holding History

Cubist Systematic Strategies’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-84,930
Closed -$902K – 3141
2024
Q4 		$902K Buy
+84,930
New +$1.03M 0.01% 1855
2024
Q3 		– Sell
-19,421
Closed -$235K – 3221
2024
Q2 		$235K Sell
19,421
-54,117
-74% -$847K ﹤0.01% 2449
2024
Q1 		$1.81M Buy
73,538
+63,292
+618% +$1.28M 0.01% 1727
2023
Q4 		$110K Buy
10,246
+9,947
+3,327% +$82.7K ﹤0.01% 3159
2023
Q3 		$2.5K Buy
+299
New +$2.2K ﹤0.01% 3197

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Cubist Systematic Strategies's IMNM Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Immunome (IMNM) in Q1 2025, closing a stake of 84,930 shares — an estimated $902K sold.

Cubist Systematic Strategies first reported a position in IMNM in Q3 2023 and held it in 5 quarters. The position peaked at $1.81M in Q1 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining Immunome position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 84,930 Immunome shares in Q1 2025, an estimated $902K.
  • Cubist Systematic Strategies first reported a position in Immunome in Q3 2023 and held it in 5 quarters.
  • Cubist Systematic Strategies's Immunome position peaked at $1.81M in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.